Video abstract of an original research paper “Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease” published in the open access journal Patient Preference and Adherence by Nakamura K, Watanabe N, Ohkawa H, et al. Background: In this study, we evaluated changes in functioning and caregiver burden in Alzheimer’s disease (AD) patients after a dosage increase that was made based on pharmacists’ evaluation of AD patients’ behavior in daily life. Methods: Pharmacists used a checklist, a questionnaire, and the Repetitive Saliva Swallowing Test (RSST) to gather data on the daily life of AD patients taking donepezil 5 mg/day and their caregivers. In 27 cases, pharmacists suggested a dosage change to 10 mg/day to AD patients’ physicians. Pharmacists then evaluated these patients for 16 weeks after the increase to determine changes in functional assessment staging, caregiver burden, and swallowing function. Results: During the 16-week study, 20 of the 27 patients showed at least one-stage improvement in relation to the five assessed aspects of daily life (time/place, speech, bathing, dressing, and toileting). The mean score for caregiver burden due to personal strain was significantly lower after the dosage increase than before (5.15±3.76 at baseline; from 3.89±3.42 at week 4 to 3.59±3.90 at week 16; P less than 0.05), as was the mean score due to role strain (2.19±2.80 at baseline; 1.56±2.64 at week 8; P less than 0.05). After the dosage increase, the impaired swallowing function that accompanies AD was improved in the patients with swallowing problems, as indicated by a higher mean RSST score (1.22±0.67 at baseline; from 2.78±1.72 at week 4 to 2.78±1.79 at week 16; P less than 0.05). Conclusion: The dosage increase not only decreased caregiver burden, but also appeared to improve impaired swallowing function. Medication therapy management by pharmacists of AD patients, including the use of a checklist, contributed to the correct use of donepezil and improved quality of life for caregivers. Read the original research paper here: http://www.dovepress.com/effects-on-caregiver-burden-of-a-donepezil-hydrochloride-dosage-increa-peer-reviewed-article-PPA
Views: 3363 Dove Medical Press
http://www.alzheimer-herbs.com ALZHEIMER'S ALTERNATIVE TREATMENT AND PREVENTION http://www.alzheimer-herbs.com Although current medications cannot cure Alzheimer's or stop it from progressing, they may help lessen symptoms, such as memory loss and confusion, for a limited time. Types of drugs.The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept, Exelon, Razadyne, Cognex) and memantine (Namenda) — to treat the cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning) of Alzheimer's disease. As Alzheimer's progresses, brain cells die and connections among cells are lost, causing cognitive symptoms to worsen. While current medications cannot stop the damage Alzheimer's causes to brain cells, they may help lessen or stabilize symptoms for a limited time by affecting certain chemicals involved in carrying messages among the brain's nerve cells. Doctors sometimes prescribe both types of medications together. Some doctors also prescribe high doses of vitamin E for cognitive changes of Alzheimer's disease. All of the prescription medications currently approved to treat Alzheimer's symptoms in early to moderate stages are from a class of drugs called cholinesterase inhibitors. Cholinesterase inhibitors are prescribed to treat symptoms related to memory, thinking, language, judgment and other thought processes. Cholinesterase inhibitors: Prevent the breakdown of acetylcholine (a-SEA-til-KOH-lean), a chemical messenger important for learning and memory. This supports communication among nerve cells by keeping acetylcholine levels high. Delay worsening of symptoms for 6 to 12 months, on average, for about half the people who take them. Are generally well tolerated. Three cholinesterase inhibitors are commonly prescribed: Donepezil (Aricept) is approved to treat all stages of Alzheimer's. Rivastigmine (Exelon) is approved to treat mild to moderate Alzheimer's. Galantamine (Razadyne) is approved to treat mild to moderate Alzheimer's. A second type of medication, memantine (Namenda) is approved by the FDA for treatment of moderate to severe Alzheimer's. Memantine is prescribed to improve memory, attention, reason, language and the ability to perform simple tasks. It can be used alone or with other Alzheimer's disease treatments. There is some evidence that individuals with moderate to severe Alzheimer's who are taking a cholinesterase inhibitor might benefit by also taking memantine. Donepezil (Aricept) is the only cholinesterase inhibitor approved to treat all stages of Alzheimer's disease, including moderate to severe. Memantine: Regulates the activity of glutamate, a different messenger chemical involved in learning and memory. Delays worsening of symptoms for some people temporarily. Many experts consider its benefits similar to those of cholinesterase inhibitors. [alzheimer's memory enhancing drugs] [alzheimer's new drug developments] [alzheimer's new drug treatment] [alzheimer's new drug trials] [alzheimer's non drug treatments] [alzheimer's prescription drugs] [alzheimer's prevention drugs] [alzheimer's psychotropic drugs] [alzheimer's reversal drug] [alzheimer's sedative drugs] [alzheimer's skin cancer drugs] [alzheimer's smart drugs]
Views: 1191 Anand Krish
In this video, Dr. Gayatri Devi, board-certified neurologist and author of The Spectrum of Hope: An Optimistic and New Approach to Alzheimer’s Disease, discusses the medications used to treat Alzheimer’s. There are two major classes of medication—the first promotes brain cell health and includes the medication Namenda…the second class increases levels of certain chemicals within the brain, and includes Aricep, Rivastigmine, Galantamine and the Exelon patch. Dr. Devi notes that this latter class is more likely to cause side effects, including nightmares, upset stomach, loose bowels, runny nose, metallic taste in the mouth and leg cramps. To reduce side effects, patients should start with the smallest doses possible.
Views: 65 Bottom Line Inc